Alan Brochstein, also known as the 420 Investor, joined Benzinga’s PreMarket Prep to discuss some of the top marijuana stocks.
The Popular Play
When it comes to one of the most popular marijuana plays on the market, GW Pharmaceuticals PLC-ADR GWPH, Brochstein says the stock will likely continue to trade sideways until the company submits its New Drug Application (NDA) for epidiolex. The NDA submission has already been delayed several times and is now expected to happen in mid-2017.
“The good thing for investors is this company is doing everything it can to make sure that that NDA doesn’t have any sort of deficiencies that would lead to any delays, so I’m excited about the company’s long-term prospects,” he explained.
Miracle Gro
When Benzinga asked about indirect marijuana play Scotts Miracle-Gro Co SMG 0.14%, Brochstein pointed out that its cannabis assets, which it plans to spin-off in the future, only represent about 10 percent of total sales.
“I don’t think you can invest in this company for that. If you like this company, it’s something to keep in mind. But the stock’s going to move on a lot of other things before it moves on cannabis,” he said.
Not A Pot Stock?
Brochstein noted that, while he understands why marijuana investors are interested in Zynerba Pharmaceuticals Inc ZYNE 1.86%’s cannabinoid treatments, it’s only loosely related to marijuana.
Brochstein points out that companies like Zynerba, which is working on synthetic ZBD, aren’t friendly to the organic marijuana business. If synthetic cannabinoid drugs win out, Brochstein says organic growers could get left behind.
“I follow [Zynerba], but I don’t really maintain an opinion on it… I think investors like to play on this marijuana theme—they think it’s helpful. I can see why people are interested in Zynerba, but Cara Therapeutics—nothing to do with cannabis.”
WEED
Brochstein also mentioned Canopy Growth Corp (TSE: WEED), which he noted is a client of his, has been under some pressure recently. Despite that, it has maintained…
Click here to continue reading
Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!
